SNS COLLEGE OF PHARMACY

AND HEALTH SCIENCE

UNIT 1

COURSE NAME: PHARMACOLOGY II

TOPIC: ANTIHYPERLIPIDEMIC DRUGS

2 MARKS

S.No	Questions	Mapping from TNMGRMU/GPAT/MRB/Various Pharma Company with Year	Bloom's Taxonomy
1	Define hyperlipidemia and classify it based on Fredrickson classification.	TNMGRMU March 2023 (Sept 2022 session); GPAT 2021 (Q on lipid disorders); MRB 2022; Cipla Interview 2023 (basic definitions).	Remembering
2	List two HMG-CoA reductase inhibitors with examples.	TNMGRMU March 2025; GPAT 2020 (statin examples); MRB 2023; Dr. Reddy's Interview 2022 (cholesterol synthesis inhibitors).	Remembering
3	State the mechanism of action of fibrates in hypertriglyceridemia.	TNMGRMU May 2024; GPAT 2019 (PPAR-alpha activation); MRB 2022; Sun Pharma Interview 2023 (TG reduction).	Understanding
4	Name two bile acid sequestrants used in hypercholesterolemia.	TNMGRMU May 2022 (Sept 2021); GPAT 2022 (resins); MRB 2023; Lupin Interview 2021 (cholesterol absorption).	Remembering
5	Differentiate between LDL and HDL in terms of function and clinical significance.	TNMGRMU Dec 2023 (Sept 2023); GPAT 2021; MRB 2022; Aurobindo Interview 2024 (lipoprotein roles).	Understanding

SNS COLLEGE OF PHARMACY

AND HEALTH SCIENCE

SNS COLLEGE OF PHARMACY AND HEALTH SCIENCES

PHARMACOLOGY|ANTIHYPERLIPIDEMICS|MS.LAVANYAA. E|AP|SNSCPHS

5 MARKS

S.No	Questions	Mapping from TNMGRMU/GPAT/MRB/Various Pharma Company with Year	Bloom's Taxonomy
1	Explain the classification of antihyperlipidemic drugs based on mechanism of action.	TNMGRMU March 2023 (Sept 2022); GPAT 2020 (classification MCQs); MRB 2023; Cipla R&D 2022 (lipid-lowering categorization).	Understanding
2	Describe the properties of ideal antihyperlipidemic agents for long-term therapy.	TNMGRMU Oct 2024 (Sept 2024); GPAT 2019; MRB 2022; Dr. Reddy's 2023 (cardiovascular risk reduction criteria).	Understanding/Analyzing
3	Discuss the role of PCSK9 inhibitors in statin-intolerant patients with examples.	TNMGRMU Aug 2023 (March 2023); GPAT 2022 (monoclonal antibodies); MRB 2023; Sun Pharma 2024 (LDL receptor upregulation).	Applying/Analyzing
4	Write notes on advantages of ezetimibe as an adjunct to statin therapy.	TNMGRMU Dec 2021 (March 2021); GPAT 2021; MRB 2022; Lupin Interview 2023 (cholesterol absorption inhibition).	Evaluating
5	Outline the applications of combination lipid-lowering therapy with one example each.	TNMGRMU May 2024; GPAT 2023; MRB 2023; Aurobindo 2022 (statin + fibrate design).	Applying

SNS COLLEGE OF PHARMACY

AND HEALTH SCIENCE

SNS COLLEGE OF PHARMACY AND HEALTH SCIENCES

PHARMACOLOGY|ANTIHYPERLIPIDEMICS|MS.LAVANYAA. E|AP|SNSCPHS

10 MARKS

S.No	Questions	Mapping from TNMGRMU/GPAT/MRB/Various Pharma Company with Year	Bloom's Taxonomy
1	Discuss the introduction, pathophysiology of atherosclerosis, classification, properties, advantages, and applications of antihyperlipidemic drugs.	TNMGRMU March 2025; GPAT 2020 (comprehensive essay); MRB 2023 (dyslipidemia overview); Cipla Senior R&D 2023 (full CV risk discussion).	Analyzing/Evaluating
2	Elaborate on the role of statins in designing primary and secondary prevention strategies, including mechanisms and examples.	TNMGRMU Dec 2021 (March 2021); GPAT 2019 (pleiotropic effects); MRB 2022; Dr. Reddy's 2024 (event reduction Q).	Analyzing/Creating
3	Explain the pharmacokinetic and pharmacodynamic properties of fibrates in mixed dyslipidemia, with advantages and limitations.	TNMGRMU Oct 2022 (March 2022); GPAT 2022; MRB 2023; Sun Pharma 2023 (TG kinetics interview).	Evaluating
4	Describe the classification and applications of novel lipid-lowering agents (PCSK9i, bempedoic	TNMGRMU Aug 2023 (March 2023); GPAT 2021 (emerging therapies); MRB 2022; Lupin 2024 (genetic hypercholesterolemia).	Applying/Analyzing

	acid, inclisiran) in resistant hyperlipidemia.		
5	Discuss statin-based vs. non-statin-based therapy in hyperlipidemia: properties, advantages, and clinical/formulation examples.	TNMGRMU March 2023 (Sept 2022); GPAT 2023; MRB 2023; Aurobindo Interview 2022 (guideline-based approach).	Evaluating/Creating